Danish pharmaceutical company Novo Nordisk has announced plans to invest 15.9 billion Danish crowns ($2.3 billion) in expanding its production facility in Denmark. The facility currently produces active pharmaceutical ingredients (API), the main biologically active components of medications, and will now be expanded to produce material for both current and future products.
The expansion of the facility will not include semaglutide, which is the key ingredient in Novo Nordisk's highly popular diabetes and weight-loss drugs, Ozempic and Wegovy. These drugs have recently faced major supply constraints, as demand for Wegovy unexpectedly soared during its launch in the United States in 2021. In response, the company has invested heavily to increase the supply of semaglutide.
Novo Nordisk's head of product supply, quality and IT, Henrik Wulff, expressed his excitement about the investment, saying, "this important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide." However, it is worth noting that construction of the new facility is currently underway, and it is not expected to start producing API until early 2029.
Novo Nordisk currently produces API at two facilities in Denmark and one in Clayton, North Carolina. Last year, the company also announced plans to invest 5.4 billion crowns to expand facilities in Bagsvaerd, Denmark. This new investment represents a significant move for the company, as it continues to expand its production capabilities in order to meet the growing demand for its products.